Regeneron Pharmaceuticals, Inc. $REGN Stock Position Lowered by Capital International Inc. CA

Key Points

• Capital International Inc. CA decreased its position by 47.3% in Regeneron during Q3, selling 33,485 shares and leaving it with 37,370 shares valued at about $21.01 million.
• Regeneron beat quarterly estimates with EPS of $11.44 (vs. $10.74) and revenue of $3.88 billion (vs. $3.76 billion); analysts have a consensus "Moderate Buy" rating and a $802.27 target price.
• The company raised its quarterly dividend to $0.94 (annualized $3.76, ~0.5% yield), while insiders have sold roughly 5,274 shares (~$4.14M) in the past three months, leaving insiders owning 7.02% of the stock.

Capital International Inc. CA decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 47.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,370 shares of the biopharmaceutical company's stock after selling 33,485 shares during the quarter. Capital International Inc. CA's holdings in Regeneron Pharmaceuticals were worth $21,012,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Salomon & Ludwin LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $31,000. Caitlin John LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Traub Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $38,000. Finally, Berbice Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 60 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $772.03 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The firm's 50 day simple moving average is $770.79 and its 200-day simple moving average is $692.02. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The company has a market cap of $81.62 billion, a P/E ratio of 18.58, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $12.07 EPS. The firm's quarterly revenue was up 2.5% on a year-over-year basis. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a $0.94 dividend. The ex-dividend date was Friday, February 20th. This is an increase from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.05%.

Insiders Place Their Bets

In other news, Director Bonnie L. Bassler sold 1,500 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares of the company's stock, valued at $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 5,274 shares of company stock worth $4,142,738 over the last three months. Company insiders own 7.02% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on REGN shares. Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a "sector perform" rating in a research note on Monday, March 2nd. Oppenheimer restated an "outperform" rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an "equal weight" rating in a research report on Monday, February 2nd. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an "outperform" rating in a research note on Thursday, December 4th. Finally, Evercore lifted their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.